This study documented the HIV-1 subtype distribution in 2 Belgian hospitals and determined predictive demographics for non-B subtypes. Overall, subtype B was the most prevalent subtype in this population, followed by subtypes A and C. Several recombinants were detected, circulating recombinants as well as new ones. We found a rise in non-B subtypes from 0% in 1983 to 57% in 2001. The Cochran-Armitage trend test (P < 0.001) as well as the correlation analysis (R = 0.71, P = 0.0006) was highly significant. Recombinants were also increasing in this patient population from 0% in 1983 to 10% in 2001, with good support from the statistical analyses (trend test P < 0.001; correlation analysis R = 0.67, P = 0.0016). Heterosexual route of infection, black African race, African origin of the virus, and year of diagnosis were predictors for infection with non-B subtypes in multivariate analysis. This analysis indicates that the prevalence of non-B subtypes and recombinants in this patient population is high and increasing. Gathering demographic and sequence information from newly diagnosed patients could be useful to further follow the spread of non-B subtypes in Belgium and Europe, but subtyping based on sequence information still remains the most reliable method.
T wo types of HIV exist, HIV-1 and HIV-2. HIV-1 is classified into 3 groups, M, N, and O, of which group M contains at least 10 subtypes, A to K, while HIV-2 contains at least 5, subtypes A to E. 1 Furthermore, circulating recombinant forms (CRFs) were discovered. 2 These are recombinants of Ն2 pure subtypes of which 3 near full-length genomes or 2 complete genomes and partial sequence information of a third strain are available and that are already taking part in the epidemic. Also, a number of other recombinants are known that have been found only in single cases up to now. 3 In the beginning of the epidemic, subtype B seemed to be dominant in the developed world (Europe, North America, and Australia), while the epidemic in the developing world was more heterogeneous. 4, 5 It has been reported that several non-B subtypes are now prevalent in former subtype B regions. [6] [7] [8] [9] [10] [11] [12] [13] Reports on changes in local HIV epidemics are scarce and the monitoring of the introduction of new subtypes or recombinants is not yet well established. This monitoring is important, because the sequence diversity of HIV has implications for detection assays, resistance monitoring, development of drug resistance, therapy response, drug design, and vaccine design. Hybridization-based techniques, like heteroduplex mobility assay for subtyping, 14 polymerase chain reaction techniques for the genotypic detection of resistance, 15 and diagnostic viral RNA quantification tests are not always equally efficient in the detection of non-B subtypes. 16, 17 An increasing number of reports describe differences in biologic phenotypic properties of viruses of different subtypes, 18 in vitro properties of viral enzymes between subtypes, 19 prevalence of resistance mutations, 20, 21 resistance development in vitro and in vivo, 22 and therapy response in patients infected with non-B subtypes. [23] [24] [25] Vaccine strategies should take into account the different subtypes or recombinants that are circulating in an area. The introduction of new subtypes can slow vaccine development and vaccine trials, because efficacy of protection may depend on the subtype. 26 In Belgium, already in 1994, the prevalence of non-B subtypes was reported to be 32%, of which subtype A was the most prevalent. 9 In the Leuven University Hospitals, in 1999, subtype B still accounted for the majority (51%) of the infections, but the prevalence of the different non-B subtypes was very high. There were also some recombinants present, mostly CRF_02, an AG recombinant, and already some unique recombinants with new recombination patterns. 27 In this study, we documented the changes in the prevalence of non-B subtypes and recombinants over the past 2 decades in 2 Belgian University hospitals. Using statistical methods we tried to define demographic variables predictive for infection with a non-B subtype virus.
MATERIALS AND METHODS

Patient Population
We included 281 patients diagnosed HIV positive between 1983-2001. One cohort consisted of 119 patients in follow-up at the Saint-Pierre University Hospital in Brussels. These patients were taking part in a study to assess the use of saquinavir soft gel in heavily pretreated patients (patients who experienced multiple virologic failures under protease inhibitor-based regimens that did not include saquinavir). The other 162 patients, both treatment naive and experienced, were in follow-up at the Leuven University Hospitals in Leuven. They had a genotyping done because they would start or change therapy or were newly diagnosed. Pol sequences were available for both groups of patients. Patient characteristics and demographics were gathered retrospectively from their files and are represented in Table 1 . Demographics in the files were based on the physician's interview with the patient. The physician includes the information that is most likely to be true. Following information was collected: gender, birth date, therapy history (naive or treated patient), year of diagnosis (the year of the first positive HIV test), race (black African, white, Asian, Latin American), origin of the virus (the most probable geographic area where the patient was infected), route of infection (the most probable transmission mode), viral load, and CD4 + count (at the time the sample was taken).
Subtyping
Subtyping was done based on the pol region, as was previously described by Snoeck et al. 27 Sequences were aligned with a set of reference sequences of group M subtypes available in the Los Alamos Database (http://hiv-web.lanl.gov) using CLUSTALX (Thompson. ftp://ftp-igbmc.ustrasbg.fr/pub/ClustalX). The alignment was then edited using GENEDOC (Nicholas. http://www.psc.edu/biomed/genedoc). Simplot, version 2.5, used to generate similarity plots and bootscans to check for possible recombinants. Sequences were scored as pure subtypes or recombinants based on their bootscanning pattern. Recombination breakpoints were determined visually by looking at the alignment and by a detailed bootscan of the query sequence and 3 reference subtypes, 2 of which would be the candidate subtypes for the recombination. 28 The subsequent detailed phylogenetic analysis was done using the PHYLIP software package, version 3.57 (Filsenstein. http://evolution.gs.washington.edu/phylip/getme. html). For CRF strains that were a single subtype in the analyzed pol region, assignment to the CRF was based on separate clustering of the CRF within the respective subtype; e.g., CRF_01 is subtype A in the analyzed pol region, but all CRF_01 strains form a separate cluster within subtype A.
Statistical Analysis
The year of diagnosis was divided into 6 groups, with 3 years in each group (the first group contains 4 years). To study the change in the prevalence of non-B subtypes and recombinants in time, we performed 2 analyses. First we did a Cochran-Armitage exact test for trends. Results are reported as P values. If the P value is <0.05, there is support for a trend. In addition, we performed a correlation analysis. Results are reported as R values.
Univariate analysis was done using logistic regression to determine the factors associated with a non-B subtype infection. Significant factors were then included in the multivariate analysis. The multivariate analysis was performed using logistic regression with a full model submitting all covariates that showed statistical significance in the univariate analysis, i.e., 1 is not included in 95% CI for the odds ratio estimate. Results were reported as the odds ratio with a 95% CI.
RESULTS
Patient Population
The demographic variables are illustrated in Table 1 . Identified were 281 patients, who were predominantly male (65%). The mean age at the time that the blood sample was taken was 41 years. Twenty-eight percent of the patients were black African and 68% white. Heterosexual route of infection was most common (48%), followed by homosexual contact (36%), infection by blood products (6%), and infection by IV drug use (2.5%). In 112 patients (40%) the resistance test was done before starting therapy; in the remaining 169 (60%), the regimen was failing at sampling time. Almost half of the patients were diagnosed HIV positive <4 years before the sample was taken.
The epidemic in our patient population has changed during the studied period. From the early 1990s on, the prevalence of homosexual infections was decreasing from 50% in the first time period (1983) (1984) (1985) (1986) ) to 33% in the last period (1999) (2000) (2001) , and the prevalence of heterosexual infections was rising from 27 to 57% over the same periods. The number of black African immigrants in our population was also increasing from 5% in the first period and stabilized at 31% in the last period. The number of white patients with a non-B subtype infection that acquired the infection in Western Europe or the United States was also increasing. The first such patient was diag-nosed in 1990, but in 2001 10% of the patients were white with a non-B subtype virus and no direct link to endemic regions (data not shown).
The characteristics of the patient populations were comparable between the 2 hospitals. The distributions in gender, age, origin of the virus, race, route of infection, viral load, CD4 + count, and subtype were not found to be different. Both therapy experience and the year of diagnosis were found to be significantly different between the 2 groups due to the nature of the selection of the both populations (data not shown).
Subtype Distribution
Overall, subtype B was the most prevalent subtype in this population (52%). Subtypes A and C were equally preva- 
Evolution in Time of the Subtype Distribution
The evolution in time was studied with respect to the year of diagnosis of the patient. The prevalence of non-B subtypes was found to be slowly increasing during the studied period, as well in Leuven as in Brussels (Fig. 1A) . This increase was significant, from 0% in 1983 to 47% in 2001. The Cochran-Armitage exact test showed a P value <0.001. We found an association between the year of diagnosis and being infected with a non-B subtype (R value of 0.71; P = 0.0006). The first non-B subtype was detected in a patient diagnosed HIV positive in 1985. The early non-B subtype infections were all diagnosed in African patients or patients who had acquired the infection outside Europe. The first non-B subtype virus population that was acquired in Western Europe was a subtype A virus sampled in a white man in 1990.
In the early 1980s, there were only a few infections with recombinant viruses (0% in 1983). In a later period, especially from 1997 onward, their proportion is rising (10% in 2001) (Fig. 1B) . The trend test gave a P value <0.001. The R value for this correlation analysis was 0.67 (P = 0.0016). The first recombinant was detected in a patient diagnosed in 1989. This was a complex divergent virus, isolated from an African patient, infected in Africa. Already in a sample from 1990 we documented the first CRF in this patient population, a CRF_06 (AGJ recombinant). In a sample from 1993, we documented the first patient who acquired a recombinant virus in Western Europe, a CRF_01. At later stages in the epidemic, from 1994 onward, we also detected several recombinants with new breakpoint patterns.
Factors Associated With Non-B Subtype Infection
We determined the factors predictive for harboring a non-B subtype virus. Results of the univariate and multivariate analysis are represented in Table 2 . Gender, race, route of infection, origin of the virus, and year of diagnosis seemed to be significantly associated with non-B subtypes in a univariate analysis. Other variables mentioned in Table 1 were not significant. These variables were then included in the subsequent multivariate analysis. The year of diagnosis was predictive for non-B infection. The earlier the patient was diagnosed, the smaller the chance that he was infected with a non-B subtype virus. Heterosexual transmission of the virus, black African 
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race, and African origin of the virus were 3 other predictors. Female gender was found to be significant in the univariate analysis, but not in the multivariate one. When keeping all variables that had P < 0.25 in the univariate analysis ( 2 analysis) in the multivariate model and calculating the odds for each of them, no additional factors were found to be independently associated with non-B subtype infection.
DISCUSSION
The HIV epidemic is ever evolving and the spread of subtypes is a known fact. Despite this knowledge, the monitoring of the introduction of new subtypes in local areas and the diversification of the virus are not yet well documented.
In Belgium a high prevalence of non-B subtypes had already been reported in 1996. 9 Our study confirms a high prevalence of non-B subtypes, compared with the neighboring countries. [6] [7] [8] 10, 11, 29, 30 In the population studied, the first non-B subtype was detected in a patient diagnosed HIV positive in 1985. In the beginning of the epidemic, infections with non-B subtype viruses were restricted to African patients or patients who acquired the infection outside Europe. Already in 1990, however, we documented the first non-B subtype infection in a white patient that was acquired in Western Europe. Since the beginning of the epidemic, the prevalence of non-B subtypes has increased significantly.
The prevalence of recombinants was also rising, with a large increase in the late 1990s. Most of the first documented cases of recombinants were CRFs, which is logical because most of these CRFs have been around for a long time. Three epidemiologically unlinked sequences or 2 sequences with partial information of a 3rd strain are needed to claim a CRF. The first documented CRF in this patient population was detected in 1990, a CRF_06 (AGJ) only described in 1998. 31 Since assignment to the subtypes was based on the pol region sequenced, more strains may be of the recombinant type than the ones identified here.
Using logistic regression we determined several demographic characteristics that were predictive for infection with a non-B subtype. Year of diagnosis, heterosexual exposure to the virus, black African race, and African origin of the virus were significant predictors of non-B subtype infections. However, since origin of the virus and route of infection are the most probable estimate, these conclusions should be taken with care. Subtype B has dominated the early epidemic in Belgium, as in other European countries. Therefore, patients who acquired the infection a long time ago were probably more likely to be infected with a subtype B virus. In this population, only from the mid-1990s onward did non-B subtypes play an important role, and half of the patients were infected before that time. Female gender was not significant in the multivariate analysis. This variable is not an independent predictor of non-B subtype infection, as it is linked with heterosexual transmission, which was a very strong predictor. The majority of women were infected heterosexually, while the majority of men are infected homosexually. African origin of the virus was significant in the multivariate analysis, but the odds were a lot lower than in the univariate analysis, while the odds ratios for race were also significant and similar in univariate and multivariate analysis. Since African origin of the virus is at least in part linked with the race, it is logical to assume that both predictors are not entirely independent. The epidemic in Africa is more diverse and all different subtypes and a lot of recombinants are present there. 4, 5 Subtype B is mostly restricted to northern Africa and South Africa and of very low prevalence elsewhere; therefore viruses of African origin will more likely belong to non-B subtypes. Also, black African patients are most likely immigrants who have acquired the infection in their country of birth, with a greater chance of being infected with a non-B subtype virus.
The rise of non-B subtype prevalence in this patient population, and probably also in other European countries, is therefore most likely correlated with a rise in heterosexual infection acquired in African endemic regions or from black Africans. This is probably due to the increase of African immigrants and to extensive traveling of Europeans to other continents. 32 We could already see that the second-generation non-B infections that take place in the European population often happen between 2 white persons, with only an indirect link to the African continent. These African viruses will start spreading within the white European population.
This study not only showed statistical support for an increasing prevalence of non-B subtypes and recombinants in Belgium but also provided demographic variables that were predictive for infection with a non-B subtype virus. Thus, gathering accurate demographic data on newly diagnosed patients can already give a first idea of the likelihood that the infecting virus belongs to a non-B subtype; yet sequence information is needed to reliably determine the subtype. When more results become available about resistance development and therapy response in patients infected with a non-B subtype virus, monitoring changes in the HIV epidemic may become even more important, especially for designing vaccine trials, development of new drugs, and optimizing individual patient treatment.
